Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

641 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, Kaszuba A, Kolodsick J, Yang FE, Gamalo M, Brinker DR, DeLozier AM, Janes JM, Nunes FP, Thyssen JP, Simpson EL. Reich K, et al. Among authors: peris k. JAMA Dermatol. 2020 Dec 1;156(12):1333-1343. doi: 10.1001/jamadermatol.2020.3260. JAMA Dermatol. 2020. PMID: 33001140 Free PMC article. Clinical Trial.
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Sirna R, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavò SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Savi E, Stingeni L, Romano A, Argenziano G; Dupilumab Italian National Access Program (Dup-INAP group). Fargnoli MC, et al. Among authors: peris k. J Dermatolog Treat. 2021 Aug;32(5):507-513. doi: 10.1080/09546634.2019.1682503. Epub 2019 Oct 28. J Dermatolog Treat. 2021. PMID: 31647347 Free article.
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L, Malvaso D, Chiricozzi A, Tambone S, D'Urso DF, Guerriero C, Peris K. Calabrese L, et al. Among authors: peris k. Expert Opin Investig Drugs. 2020 Oct;29(10):1089-1098. doi: 10.1080/13543784.2020.1800639. Epub 2020 Aug 14. Expert Opin Investig Drugs. 2020. PMID: 32703039 Review.
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL; ECZTRA 1 and ECZTRA 2 study investigators. Wollenberg A, et al. Among authors: peris k. Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30. Br J Dermatol. 2021. PMID: 33000465 Free PMC article. Clinical Trial.
Targeting IL-4 for the Treatment of Atopic Dermatitis.
Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Chiricozzi A, et al. Among authors: peris k. Immunotargets Ther. 2020 Sep 29;9:151-156. doi: 10.2147/ITT.S260370. eCollection 2020. Immunotargets Ther. 2020. PMID: 33062619 Free PMC article. Review.
641 results